Skip to content


Pharmaceuticals & Biotechnology
Exit type:
Partial Exit

Scancell is advancing a universal COVID vaccine which may be effective against all variants.

Scancell is progressing towards regulatory approval to start a
Phase 1/2 clinical study in the UK in 2021 for Modi-1, based on
its Moditope® platform, which targets triple negative breast,
ovarian, head and neck, and renal cancer, as well as many
other cancers. SCIB1, Scancell’s lead product based on its
Immunobody platform, is being developed for the treatment
of metastatic melanoma.

Due to increase in the share price we were able to exit earlier investors.

Past performance is not a guide to future performance.